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Where Are We Now?
T
argeted therapeutics are nee-
ded to improve the prognosis
of patients with osteosarcoma.
Since the introduction of chemother-
apy in the 1980s, 5-year survival
for the often young patients with
osteosarcoma has plateaued at about
50% to 60%. For patients with
metastases, the outcomes remains
particularly poor. By performing a
serial analysis of a gene expression
experiment comparing osteosarcomas
with normal osteoblasts and mes-
enchymal stem cells, the authors
identified the insulin-like growth factor
(IGF) pathway and the transforming
growth factor-b (TGF-b) pathway as
possible targets for therapy. Since the
effects of stimulation or inhibition of
the TGF-b pathway on osteosarcoma
cell proliferation is debatable [9], and
the developed TGF- b pathway
inhibiting agents elicit unwanted
effects [13], we will focus on the
possibility of targeting the IGF path-
way in osteosarcoma.
The current paper emphasizes that
the IGF pathway plays an important
role in osteosarcoma pathogenesis,
which is supported by other preclinical
studies showing reduced proliferation
in the majority of osteosarcoma cell
lines [7] and xenografts [6] upon
IGF 1 receptor (IGF-1R) inhibition.
In addition, the peak incidence of
osteosarcoma correlates with the
increased levels of growth hormone
and IGF ligands in puberty, and it has
been described that the expression of
several IGF pathway members (IGF-
1R, IGF-1, growth arrest-specific 6,
and IGF binding proteins 4 [IGFBP4])
correlates with osteosarcoma progno-
sis [4, 7]. However, clinical trials
demonstrate that only a small subset of
osteosarcoma patients respond to IGF-
1R antibodies [3]. This illustrates the
general trend with IGF-1R inhibitors.
Although preclinical models have
shown promising results, evidence for
their efficacy in large-scale random-
ized controlled trials is lacking. As a
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consequence, pharmaceutical compa-
nies have discontinued the production
of all IGF pathway targeting agents.
Where Do We Need To Go?
The current paper emphasizes the
importance of IGF signaling in the
development of osteosarcomas. Despite
the fact that only a subset of patientswith
osteosarcoma are sensitive to IGF-1R
inhibition, the strong preclinical ratio-
nale deserves further clinical and
translational exploration. Predictive
biomarkers to identify the subset of
patients that will benefit from IGF-di-
rected therapy should be identified. The
most obvious biomarker would be
expression of the IGF-1R, but a Phase 2
trial with Cixutumumab (IGF-1R anti-
body) and Temsirolimus (mTOR
inhibitor) in patients with bone and soft-
tissue sarcomas showed that IGF-1R
expression does not correlate with ther-
apeutic response [11]. However, the
search for biomarkers is ongoing, and
several other biomarkers have been
proposed, such as mutated Kirsten rat
sarcoma viral oncogene homolog
(KRAS) and phosphorylated extracellu-
lar signal-regulated kinases (ERK) [5].
Besides the identification of predic-
tive biomarkers, the efficacy of
alternative methods to target the IGF
pathway should be explored, such as
tyrosine kinase inhibitors that target
both the IGF-1R and the insulin recep-
tor, given its crossreactivity. Once
in vitro studies identify the best
approach to target the IGF pathways,
and once biomarkers have been identi-
fied, the next step would be small
clinical trials to reevaluate the efficacy
of IGF pathway inhibitors in patients
with osteosarcoma. These clinical trials
must incorporate a strong translational
research program. Therefore, we should
convince pharmaceutical companies to
resume the production of IGF pathway
inhibitors, especially the IGF-1R/in-
sulin receptor dual inhibitors.
How Do We Get There?
One clinical trial with Linsitinib (a
dual IGF-1R insulin receptor inhibitor)
is currently being performed in Ewing
sarcoma, where IGFBP3 is downregu-
lated as a consequence of the Ewing
sarcoma breakpoint region 1-Friend
leukemia virus integration 1 fusion
gene (EWSR1-FLI-1) [10] resulting in
overactivity of the IGF pathway.
Interestingly, IGF-1R inhibition seems
promising in a subset of patients with
Ewing sarcoma [3]. This EuroSARC
study, led by Prof. Dr. Hassan from the
University of Oxford, aims to identify
predictive biomarkers by incorporating
a strong translational research program
in this clinical trial. The biomarkers
that will be identified in the
EuroSARC study should be tested in
other tumors including osteosarcoma,
and as mentioned above, new trials for
osteosarcoma, similar to this trial in
Ewing sarcoma, should be conducted.
The clinical trials that have been per-
formed in osteosarcoma thus far have
two major limitations. First, all the
studies involved IGF-1R monoclonal
antibodies. It is known that signaling
via the insulin receptor can circumvent
IGF-1R inhibition [2]. Indeed, it was
shown in osteosarcoma cells that dual
inhibition of IGF-1R and insulin
receptor is more effective than IGF-1R
inhibition alone [1]. Therefore, results
from clinical studies with dual inhibi-
tors are warranted. Second, in the
clinical trials conducted so far, IGF-
1R-targeting antibodies were adminis-
tered as a monotherapy to patients that
failed complete remission upon
chemotherapy. IGF-1R inhibitors
should be tested in combination with
chemotherapeutic agents, as it has
been described that the ligand IGF-2 is
upregulated in patients in response to
chemotherapy [12] and that in
osteosarcoma cell lines IGF-1R inhi-
bition can enhance the effect of
doxorubicin and radiotherapy [8].
The current paper strengthens the
view that the IGF pathway can be an
effective target for therapy in
osteosarcoma, thereby emphasizing
the need for the industrial facilitation
of clinical trials with IGF-1R/insulin
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receptor dual inhibitors combined with
chemotherapy, in which a strong
translational program is embedded for
predictive biomarker identification in
osteosarcoma patients.
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